Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × ruxolitinib × Clear all

NCT00638378 2018-02-12

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Phase 2 Terminated

22 enrolled 6 charts

Prostatic Neoplasms